home / stock / mgnx / mgnx articles
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2...
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 50 points on Tuesday. Here are some big stocks recording gains in today&...
ROCKVILLE, MD, Aug. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturi...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, July 03, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.com 844-916...
2024-05-23 20:30:04 ET BTIG analyst issues BUY recommendation for MGNX on May 23, 2024 06:39PM ET. The previous analyst recommendation was Buy. MGNX was trading at $4.63 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst reco...
2024-05-23 20:00:06 ET Kaveri Pohlman from BTIG issued a price target of $9.00 for MGNX on 2024-05-23 18:39:00. The adjusted price target was set to $9.00. At the time of the announcement, MGNX was trading at $4.63. The overall price target consensus is at $15.00 with hi...